|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| S |
SENSORY PRODUCTS |
| S1G |
ANTIGLAUCOMA
Glaucoma is a disease complex characterised by an increase in intraocular pressure that may damage the optic disc leading to irreversible blindness. Products being investigated include b -blockers, miotics, a 2-agonists, carbonic anhydrase inhibitors and proteoglycanase inhibitors. |
| S1Z |
OPHTHALMOLOGICAL
Ophthalmological formulations of anti-infective agents (antivirals and antibacterials) that are used to treat eye infections. Products such as anti-inflammatories for use in ophthalmological disease states, cataracts and post-operative treatment, antiallergics, ocular lubricants, treatments for diabetic retinopathy eg aldose reductase inhibitors, and wound healing compounds. |
| S2 |
OTOLOGICAL
Products that are used in the treatment of otological (ear) disorders. It includes anti-infectives (antibiotics and antifungals) that are administered directly into or onto the ear. |
top
| T |
BIOTECHNOLOGY PRODUCTS |
| T2A1 |
RECOMBINANT INTERFERON
Interferons which have been produced using recombinant DNA technology (genetic engineering). |
| T2A2 |
RECOMBINANT INTERLEUKIN
Interleukins which have been produced using recombinant DNA technology (genetic engineering). |
| T2A3 |
RECOMBINANT GROWTH FACTOR
Growth factors which have been produced using recombinant DNA technology (genetic engineering) including colony stimulating factors, transforming growth factor, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, nerve growth factor and ciliary neurotrophic factor. |
| T2B |
RECOMBINANT VACCINE
Vaccines, including cancer vaccines and contraceptive vaccines, which have been produced using recombinant DNA technology (genetic engineering). This includes prophylactic nucleic acid vaccines ('naked DNA' vaccines). |
| T2C |
RECOMBINANT HORMONE
Animal hormones which have been produced using recombinant DNA technology (genetic engineering) including calcitonin and somatomedin. |
| T2D |
LYTIC VIRUS
Replication-competent viruses, which lyse pathogenic cells directly, particularly oncolytic viruses which specifically attack cancer cells. These are normally genetically modified to render them harmless to normal tissues. |
| T2Z |
RECOMBINANT, OTHER
Proteins and their derivatives which have been produced using recombinant DNA technology (genetic engineering), except interferons, interleukins, growth factors, vaccines and hormones, which have there own sections as shown above. Recombinant molecules in development include clotting factors, cell adhesion molecules, cytokine antagonists, enzyme replacement therapies and chimaeric molecules. |
| T3A1 |
MONOCLONAL ANTIBODY, MURINE
Monoclonal antibodies which are not conjugated to another agent and which are derived from immunization of mice and rats. |
| T3A2 |
MONOCLONAL ANTIBODY, HUMAN
Monoclonal antibodies which are not conjugated to another agent and which are completely derived from humans, or have fully-human sequences. |
| T3A4 |
MONOCLONAL ANTIBODY, CHIMAERIC
Monoclonal antibodies which are not conjugated to another agent and which are engineered to contain portions derived from both human and animal sources, but are less than 70% human. This section does not include humanized antibodies (see T3A5). |
| T3A5 |
MONOCLONAL ANTIBODY, HUMANIZED
Monoclonal antibodies which are not conjugated to another agent and which are engineered to contain 90-95% human sequences, with the remainder usually consisting of rodent sequences. Fully-human monoclonal antibodies are classified separately in T3A2. |
| T3A9 |
MONOCLONAL ANTIBODY, OTHER
Monoclonal antibodies which are not conjugated to another agent and which are derived from an unknown source, or cannot be classified in other T3A categories. |
| T3B1 |
IMMUNOTOXIN
Immunotoxins are conjugates or fusion proteins of immunoglobulins (usually monoclonal antibodies) and toxins. The immunoglobulin will deliver the toxin to cells exhibiting the appropriate antigen, without the toxin coming into contact with normal cells. |
| T3B9 |
IMMUNOCONJUGATE, OTHER
Conjugates of immunoglobulins with other agents, excluding toxins, which are listed in Immunotoxin (T3B1). With all of these agents the antibody part of the molecule is used to direct it to its target, where the effector part of the molecule will perform its action. |
| T4A |
GENE THERAPY
Gene therapy is a term used to describe vector-mediated introduction of a therapeutic genetic sequence into target cells in vivo or ex vivo. Vectors may be viral or non-viral (eg plasmids). Strategies include replacement of defective or missing genes (eg for cystic fibrosis), or introduction of more broadly-acting (eg immunostimulant) sequences for the treatment of multifactorial diseases (eg cancer). Gene therapy vectors may also be used to deliver antisense and RNA interference sequences (see T4B and T4F). Lytic viruses which do not deliver therapeutic DNA are covered in T2D, and non-recombinant mammalian cells are covered in T5A (stem cells) and T5Z (other types). Direct administration of oligonucleotides without using vectors is covered separately in T4B (for antisense), T4F (for RNA interference) or T4E (for other oligonucleotide types). Platform technologies for gene delivery are covered separately in T4D. |
| T4B |
ANTISENSE THERAPY
Includes all entries for antisense compounds under development as potential therapeutics. Antisense compounds may be synthetic oligonucleotides, or antisense RNA may be expressed from a vector as a form of gene therapy (see T4A). They may prevent the expression of a specific protein in vivo by binding to and inhibiting the action of mRNA, since they have a specific oligonucleotide sequence which is complementary to the DNA or RNA sequence which codes for the protein. |
| T4D |
GENE DELIVERY VECTOR
Platform technologies for the delivery of therapeutic genes or nucleic acid vaccines. Viral and non-viral vectors (eg liposome systems) are included. Actual therapies and vaccines using these technologies are covered separately in T4A (for gene therapy) and T2B (for nucleic acid vaccines). |
| T4E |
OLIGONUCLEOTIDE, NON-ANTISENSE, NON-RNAI
Synthetic therapeutic oligonucleotides which operate by a mechanism other than antisense or RNA interference (RNAi). This includes ribozymes, aptamers, decoys, CpGs, and mismatched and immunostimulant oligonucleotides. Sequences delivered using vectors (gene therapy) are covered separately in T4A. Antisense and RNAi oligonucleotides are covered separately in T4B and T4F, respectively. |
| T4F |
RNA INTERFERENCE
Includes all entries for products which act therapeutically via an RNA interference (RNAi) mechanism, including small interfering RNAs (siRNAs). These may be synthetic oligonucleotides, or RNAi sequences may be expressed from a vector as a form of gene therapy (see T4A). In vivo, these sequences block the expression of a specific protein by forming an RNA-induced silencing complex, which then specifically binds to and degrades a complementary mRNA encoding the target protein. The use of RNAi purely as a drug discovery tool (eg in transgenic animal model production or in target validation) is not covered in this section. |
| T5A |
STEM CELL THERAPY
Non-recombinant cultured mammalian stem cells used as therapeutics. Recombinant stem cells are classified separately as ex vivo gene therapy (in T4A). |
| T5Z |
CELLULAR THERAPY, OTHER
Non-recombinant cultured mammalian therapeutic cells other than stem cells. Includes products such as dendritic cells, pancreatic islet implants, cultured wound healing products, and cultured T-lymphocytes. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home